Chantibody Therapeutics, Inc.
Chantibody Therapeutics is a biotech company based in Menlo Park, California, focused on discovering and developing transformational therapeutics, especially for cancer. They utilize a proprietary in silico empowered antibody discovery platform to create diverse biologics and modalities such as mAbs, bispecifics, multi-specific antibodies, fusion proteins, CAR-T, mRNA, and antibody conjugates. Their mission is to bring world-class antibody and next-generation therapeutics to improve human health by building a novel VHH antibody intelligence platform, generating differentiated antibodies, and maximizing value through collaboration.
Industries
Nr. of Employees
small (1-50)
Chantibody Therapeutics, Inc.
Mountain View, California, United States, North America
Products
VHH discovery platform
Integrated experimental and computational platform to discover single-domain antibody leads using repertoire NGS, ML-based analysis, and high-throughput screening.
Pathogen/tissue-derived antigen VHH bank
Collections of VHHs generated against native cell- and tissue-derived antigens including proteins, glycans, lipids, and their complexes to enable discovery of disease-specific binders.
Preclinical therapeutic candidates (multispecific and CAR-T leads)
Program-stage therapeutic candidates including multispecific single-domain antibody constructs, T-cell engager leads, and CAR-T constructs demonstrated in preclinical studies.
VHH discovery platform
Integrated experimental and computational platform to discover single-domain antibody leads using repertoire NGS, ML-based analysis, and high-throughput screening.
Pathogen/tissue-derived antigen VHH bank
Collections of VHHs generated against native cell- and tissue-derived antigens including proteins, glycans, lipids, and their complexes to enable discovery of disease-specific binders.
Preclinical therapeutic candidates (multispecific and CAR-T leads)
Program-stage therapeutic candidates including multispecific single-domain antibody constructs, T-cell engager leads, and CAR-T constructs demonstrated in preclinical studies.
Services
Computational antibody discovery and repertoire analysis service
ML- and NGS-driven analysis to identify drug‑able antibody sequences from immune repertoires and prioritize candidates for downstream engineering.
High-throughput VHH discovery and library construction
Experimental workflows to isolate antigen-specific B cells, construct VHH libraries, and screen for functional leads—including workflows tailored to CAR-T lead discovery.
Design and engineering of multispecific antibody formats
Design services for constructing multispecific antibodies and fusion proteins, including epitope geometry analysis and thermodynamics-guided linker design.
CAR-T construct development and non-viral manufacturing approaches
Engineering of CAR constructs (including dual-target and conditional activation designs) and development of non-viral approaches with reduced ex vivo culture requirements.
Computational antibody discovery and repertoire analysis service
ML- and NGS-driven analysis to identify drug‑able antibody sequences from immune repertoires and prioritize candidates for downstream engineering.
High-throughput VHH discovery and library construction
Experimental workflows to isolate antigen-specific B cells, construct VHH libraries, and screen for functional leads—including workflows tailored to CAR-T lead discovery.
Design and engineering of multispecific antibody formats
Design services for constructing multispecific antibodies and fusion proteins, including epitope geometry analysis and thermodynamics-guided linker design.
CAR-T construct development and non-viral manufacturing approaches
Engineering of CAR constructs (including dual-target and conditional activation designs) and development of non-viral approaches with reduced ex vivo culture requirements.
Expertise Areas
- Antibody discovery and engineering
- Single-domain antibody (VHH/nanobody) therapeutics
- Multi-specific antibody design
- CAR-T discovery and engineering
Key Technologies
- Next-generation sequencing (NGS) of immune repertoires
- Machine learning / antibody intelligence for sequence selection
- Single-domain antibody (VHH) libraries
- Phage display